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Abstract: Previous studies have reported continued focal gray matter loss after the clinical onset of schizophrenia.   
Longitudinal assessments in chronic illness, of white matter in particular, have been less conclusive.  
We used diffusion-tensor and structural magnetic resonance imaging in 16 healthy subjects and 49 chronic schizophrenia 
patients, subdivided into good-outcome (n=23) and poor-outcome (n=26) groups, scanned twice 4 years apart. Fractional 
anisotropy, gray matter and white matter volumes were parcellated into the Brodmann’s areas and entered into multiway 
ANCOVAs. 
At baseline, schizophrenia patients had 1) lower anisotropy in frontoparietal white matter, 2) larger posterior frontal white 
matter volumes, and 3) smaller frontal, temporal, and parietal gray matter volumes. On follow-up, healthy subjects 
showed a more pronounced 1) decline in anisotropy, 2) expansion of regional white matter volumes, and 3) reduction in 
regional gray matter volumes than schizophrenia patients. Good-outcome patients showed a more pronounced decline in 
white matter anisotropy and a less pronounced increase in white matter volumes than poor-outcome patients.   
Poor-outcome patients displayed a greater gray matter loss throughout the brain than good-outcome patients.  
In the chronic phase of the illness, longitudinal changes in both gray and white matter are in the direction of an effacement 
of between-group differences among schizophrenia patients and healthy subjects. Similarly, preexisting white matter   
differences between good-outcome and poor-outcome patients diminish over time. In contrast, gray matter volumes in 
poor-outcome patients continue to decline more rapidly than in patients with good outcome. These patterns are consistent 
with earlier onset of aging-associated changes in schizophrenia. 
Key Words: Kraepelinian schizophrenia, poor outcome, anisotropy, white matter, illness progression.  
INTRODUCTION 
  Illness progression remains a debated topic in schizo-
phrenia neuroimaging research [1, 2]. It has been convinc-
ingly demonstrated that there is a continuing loss of gray 
matter volume for a period of perhaps several years leading 
to and immediately following the first outbreak of psychotic 
symptoms (reviewed in [3, 4]). Yet, further changes in gray 
matter and the white matter dynamics over the later course of 
the illness are not as well understood. Although some 
authors reported a similarly progressive decline in gray   
matter volumes in chronic schizophrenia patients as had been 
shown after the first psychotic outbreak [5], the interpretation 
of these results gained a degree of controversy when   
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Weinberger and McClure [6] proposed that these findings in 
fact may be epiphenomenal, reflecting the methodological 
and/or physiological vicissitudes rather than a true tissue 
loss. This claim sprang from a rather obvious conjecture that 
by extrapolating the reported rate of excessive gray matter 
loss early in the illness (2-7% per year in various studies) in 
due time schizophrenia patients risk being left void of gray 
matter altogether. The possibility of a nonlinear volumetric 
change with age in patients with schizophrenia had been 
largely dismissed in the authors’ initial argumentation as was 
already pointed out by Mathalon et al. [7] in their earliest 
response to the criticisms of Weinberger and McClure. A 
more recent review of the still rare longitudinal MRI studies 
in chronic schizophrenia patients, however, concludes that 
this indeed may be the case and that, unlike normal aging, 
the rate of regional changes in both gray and white matter 
volumes in patients with schizophrenia slows down with age 
[8].  
  Brain tissue changes during the course of normal aging 
include decline in gray matter volumes and corresponding 32    The Open Neuroimaging Journal, 2009, Volume 3  Mitelman et al. 
increase in white matter volumes, but the timeframes of 
these changes are different for each tissue type (reviewed in 
[9, 10]). Thus, while gray matter loss with age follows a lin-
ear course, longitudinal white matter volume changes follow 
a reversed U-curve, expanding through the fifth decade of 
life and shrinking in the later years [11, 12]. Further, Bart-
zokis et al. point to a differential lobar topography of the 
longitudinal white matter dynamics: the volumes peak at age 
44.6 years in the frontal lobe and at the age of 47 years in the 
temporal lobe [11]. Fractional anisotropy in the white matter 
shows similar but more linear anteroposterior dynamics (see 
[13] for review). Thus, while global white matter fractional 
anisotropy decreases with age [14], frontal regions appear to 
be affected first, followed by the temporal regions with spar-
ing of the parietal and occipital lobes [15]. There is a sugges-
tion that changes in fractional anisotropy precede co-
territorial and apparently correlated volumetric changes in 
normal aging, hence may represent a more sensitive index of 
white matter aging [16-18].  
  Many longitudinal studies have recorded progressive 
decline in frontotemporal gray matter volumes in patients 
with schizophrenia over time. The vast majority of these 
studies, however, have specifically focused on the adolescent 
or young adult first-episode schizophrenia patients for   
a period of time up to 5 years following the symptomatic 
onset of the disease [19-30]. Longitudinal assessments in 
more chronic patients have been relatively few and less   
conclusive: one reporting significant volume loss [5], another - 
focal gray matter density loss [31], and 3 others - no progres-
sive changes [32-34]. van Haren et al. [35], by studying a 
longitudinal cohort of schizophrenia patients aged 16 to 56 
years, divided into subgroups based on the duration of ill-
ness, conclude that progressive gray matter volume loss in 
excess of normal aging slows down with age and is discern-
able only up to approximately 45 years of age (or ~20 years 
into the illness); this volume loss is more pronounced in pa-
tients with poor clinical outcome. Still scanter are the longi-
tudinal assessments of white matter volumes in schizophre-
nia. Ho et al. [23] documented reductions in the frontal white 
matter and Whitford et al. [36] in the posterior temporal 
white matter volumes over the 3-year period following the 
first psychotic outbreak. van Haren et al. in the above-cited 
study [35] report that white matter volumes in their patients 
were expanding with age at an ever-slowing rate until the 
expansion was no longer detectable by the age of 51 years. 
Finally, no longitudinal follow-up reports of the white matter 
anisotropy changes in patients with schizophrenia have yet 
been published, but two cross-sectional studies [37, 38] con-
clude that widespread decreases in fractional anisotropy with 
age are more pronounced in schizophrenia and are related to 
the duration of illness. 
  The goal of the present study was to investigate the pro-
gression of changes in gray and white matter volumes, as 
well as white matter fractional anisotropy, in a group of 
middle-aged patients with chronic schizophrenia. We strived 
to determine whether the illness remains uniformly progres-
sive in its chronic phase (as it appears to be around the first 
psychotic outbreak) and hypothesized that the morphometric 
evidence of the illness progression will only be evident in  
the more severe schizophrenia patients with poor clinical 
outcome. To this end, patients were divided into those with  
 
good and poor outcomes and an identical parcellation 
scheme was applied to both gray and white matter. This   
approach has previously been used in our cross-sectional 
studies on the large original sample which served as the   
recruitment base for the present follow-up [39-41], thus   
providing directly comparable longitudinal data.  
MATERIALS AND METHODOLOGY 
Subjects 
Follow-up Sample 
  The follow-up cohort comprised 49 patients with schizo-
phrenia (age at baseline scan 42.69±12.29 years; 7 women; 2 
left-handed)  and 16 healthy subjects (age at baseline 
41.63±12.23 years, t63=0.30, p=ns; 7 women; no left-
handed), scanned approximately 4 years apart (4.10±0.54 
years for schizophrenia patients and 4.22±0.52 years for 
healthy subjects, t63=0.76, p=ns). Schizophrenia patients had 
significantly lower baseline Mini-Mental State Examination 
(MMSE) scores than healthy subjects (t56=4.17, p=0.0001), 
but did not significantly differ in major demographic charac-
teristics (Table 1). These 65 participants underwent mor-
phometric analyses for regional gray and white matter   
volumes. A smaller sample of 49 participants was available 
for the diffusion-tensor imaging (DTI) analyses: this DTI 
sample comprised 13 healthy subjects and 34 schizophrenia 
patients (17 with good outcome and 17 with poor outcome). 
All participants were administered a semi-structured diag-
nostic interview with the Comprehensive Assessment of 
Symptoms and History [42]. Patients with schizophrenia 
were recruited from the inpatient and outpatient services at 
Pilgrim State Psychiatric Center, Mount Sinai and Bronx VA 
Medical Centers, - all in New York metropolitan area. The 
matched normal comparison subjects were recruited through 
advertisement. The exclusion criteria comprised a history of 
substance abuse, head trauma, neurological illness, average 
body weight that exceeded upper 25
th percentile, significant 
abnormalities on screening physical examination and labora-
tory tests (including urine toxicology screen, thyroid   
function, VDRL, B12 and folate levels).  The project was   
approved by the institutional review board of the Mount   
Sinai School of Medicine and informed consent was   
obtained from each participant. 
  Patients with schizophrenia were classified into the good-
outcome (n=23) and poor-outcome (n=26) subgroups based 
on the criteria by Keefe et al. [43, 44]. In brief, these   
required that poor-outcome patients met the following criteria 
for at least five years prior to study contact: 1) continuous 
hospitalization or complete dependence on others for food, 
clothing, and shelter; 2) no useful employment; and 3) no 
evidence of symptom remission. All other schizophrenia 
patients were considered good-outcome. Patients classified 
as poor-outcome (age 47.35±11.9 years; 1 woman) were 
significantly older at baseline scan than patients with good 
outcome (37.44±10.68 years, t47=3.05, p=0.004; 6 women), 
but did not differ in length of between-scan interval 
(3.98±0.4 years vs. 4.24±0.65 years, respectively, t47=1.76, 
p=0.09). PANSS assessments at baseline showed that pa-
tients with poor outcome, as compared to those with good 
outcome, had significantly more severe positive (22.4±6.64 
vs. 15.39±4.92, t47=4.12, p=0.00015), negative (22.36±7.40  
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vs. 15.35±5.08, t47=3.79, p=0.0004), and general psychopa-
thology scores (45.12±10.05 vs. 35.32±14.63, t47=2.7, 
p=0.01), as well as a longer duration of illness (t41=3.94, 
p=0.0003), but did not differ significantly in MMSE scores 
(t=1.6, p=0.12). Duration of illness at the initial scan date 
was conservatively constructed as time in years since the age 
of the first illness-related antipsychotic treatment. 
Comparison with Full Baseline Sample and with Subjects 
Lost to Follow-up 
  This follow-up cohort of 65 subjects was recruited as a 4-
year continuation of our baseline study of 104 patients with 
schizophrenia (51 with good outcome and 53 with poor out-
come) and 41 healthy subjects, published elsewhere [39-41, 
45-51]. In order to rule out potential sources of systematic 
bias in subject retention and attrition, we compared age and 
illness severity of the current follow-up cohort with those of 
the full baseline sample of 145 participants and with those of 
the drop-outs that were lost to 4-year follow-up (Table 1). 
There were no significant differences in age or PANSS   
subscale scores between healthy subjects, all schizophrenia 
patients, and schizophrenia subgroups by outcome in the 
comparison of the full original sample of 145 participants 
and the current follow-up cohort of 65 participants. There 
was a trend (t151=1.65, p=0.073) towards more severe general 
psychopathology PANSS subscale score in schizophrenia 
patients in the current follow-up cohort (40.53±13.23) than 
in the full original sample (37.07±9.87). 
  In the comparison of the current follow-up cohort of 65 
subjects with the drop-out sample of 80 subjects, schizo-
phrenia patients retained to follow-up (n=49) had signifi-
cantly more severe (t102=2.36, p=0.032) PANSS general   
psychopathology scores (40.53±13.23) than schizophrenia 
patients that were lost to follow-up (n=55, 35.52±10.14). 
There was also a trend towards more severe PANSS general 
psychopathology scores (t51=2.01, p=0.056) in the poor-
outcome schizophrenia patients that were retained for   
follow-up (n=26, 45.12±10.05) than in the poor-outcome 
patients that were lost to follow-up (n=27, 40.04±8.86). The 
healthy subjects, all schizophrenia patients, good-outcome 
and poor-outcome subgroups in the current follow-up   
and the drop-out samples were not significantly different 
otherwise. 
Image Acquisition and Processing 
 T 1-weighted MR images were acquired using a 1.5T 
Signa 5 scanner (GE Medical Systems) with a 3D-SPGR 
sequence (TR=24 msec, TE=5 msec, flip angle=40°, matrix 
size 256256, field of view 23 cm, slice thickness 1.2 mm, 
total slices 128, NEX=1). The diffusion tensor sequence   
acquired fourteen 7.5-mm-thick slices (TR = 10 s, TE = 99 
ms, TI = 2.2 s, b = 750 s/mm,  = 31 ms,  = 73 ms). Before 
the diffusion EPI sequence, a Turbo Spin Echo was also   
acquired to obtain a localizing anatomical image. In order to 
solve for the components of the diffusion tensor, seven diffu-
sion EPI images were obtained: six with different non-
collinear gradient weightings and one with no diffusion   
gradient applied. The diffusion tensor for every voxel in a 
slice was then computed by solving the seven simultaneous 
signal equations relating the measured signal intensity to   
the diffusion tensor. Anatomical SPGR MR images were 
resectioned to standard Talairach-Tournoux position using the 
Table 1.  Clinical and Demographic Characteristics 
Subject Group  Age at Initial Scan Date  Age at First Treatment
a  Duration of Illness
b   PANSS
c     MMSE
d 
       Positive  Negative  General   
FULL BASELINE SAMPLE (n=145) 
Healthy Subjects (n=41)  44.15±14.66           29.86±9.12 
Schizophrenia Patients (n=104)  42.77±12.12  24.96±9.12  18.49±12.71  18.86±6.64  18.91±7.77  37.07±9.87  26.86±2.71 
Good-Outcome Patients (n=51)  40.62±12.60  26.82±7.06  14.82±12.10  16.04±4.94  16.25±5.53  32.38±7.83  27.00±2.64 
Poor-Outcome Patients (n=53)  44.79±11.39  22.82±10.74  22.74±12.20  21.74±6.94  21.60±8.72  41.81±9.42  26.72±2.80 
FOLLOW-UP COHORT (n=65) 
Healthy Subjects (n=16)  41.62±12.23           30.00±0.00 
Schizophrenia Patients (n=49)  42.69±12.29  23.80±8.01  18.67±12.05  19.04±6.80  19.00±7.25  40.53±13.23  26.47±3.15 
Good-Outcome Patients (n=23)  37.44±10.68  26.81±5.51  12.29±8.78  15.39±4.92  15.35±5.08  35.32±14.63  27.32±2.36 
Poor-Outcome Patients (n=26)  47.35±11.90  20.96±9.05  24.77±11.71  22.4±6.64  22.36±7.40  45.12±10.05  25.79±3.56 
DROP-OUT SAMPLE (n=80) 
Healthy Subjects (n=25)  45.62±15.75           29.77±0.53 
Schizophrenia Patients (n=55)  43.19±12.37  25.38±9.88  18.40±13.08  18.38±6.20  19.00±8.46  35.52±10.14  27.20±2.43 
Good-Outcome Patients (n=28)  42.21±13.25  26.46±8.10  16.54±13.66  16.96±5.53  16.52±5.98  33.27±7.83  27.36±2.08 
Poor-Outcome Patients (n=27)  43.62±11.53  23.90±11.98  20.95±12.12  20.36±6.63  21.23±9.87  40.04±8.86  27.35±2.41 
aDocumented age at the time of first exposure to antipsychotic agents 
bTime (in years) since the first illness-related exposure to antipsychotic agents to the initial scan 
cPositive and Negative Syndrome Scale 
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algorithm of Woods et al. [52] and a 6-parameter rigid-body 
transformation. The anisotropy images from each subject 
were then aligned to subject’s own standard-position   
anatomical images using the same 6-parameter rigid-body 
transformation. We computed the eigenvectors and eigenval-
ues for every tensor, which created the basic raw dataset for 
subsequent analyses. The eigenvector associated with the 
largest eigenvalue, or principal diffusivity, indicates the di-
rection of the maximal apparent diffusivity, which in normal 
white matter corresponds to the orientation of the axis of an 
axonal bundle.  
Brodmann’s Area Analysis 
  Brodmann map parcellation and quantification of tissue 
types were performed exactly as in our previous reports on 
the full baseline sample, from which the present longitudinal 
cohort was drawn (cf. [47]). Briefly, we used a semi-
automated parcellation technique based on the Perry post-
mortem brain atlas (the atlas was published in [47]). This 
method splits manually traced coronal brain slices into 20 
radial and 10 midline sectors in each hemisphere, and each 
temporal lobe into 16 sectors, which are then assigned to 40 
Brodmann’s areas identified in the Perry atlas. Segmentation 
into the white and gray tissue types is done using the FSL 
program FAST with bias field correction of MRIs followed 
by kmeans clustering and local Markov analysis at each 
voxel; a binary image is created for each of the tissue types, 
which has received extensive methodological examination 
[53]. Note that in this study fractional anisotropy was aver-
aged across white matter regions underlying cortical Brod-
mann’s areas and was thus treated as general tissue property 
with no reference to particular white matter tracts. This   
averaging allows for between-group comparisons of the rates 
of longitudinal changes in regional white matter integrity. 
Similarly, quantifying regional white matter volumes in   
reference to cortical Brodmann’s areas allows the between-
group differences in longitudinal volume change to be   
regionally delineated. 
Statistical Analyses 
  In this study, we utilized a strategy used in our previous 
publications on the full baseline sample of patients with 
good and poor outcome schizophrenia (cf. [41]). The goal 
was to demonstrate significant differences in overall patterns 
of changes in regional tissue volumes and anisotropy   
between diagnostic groups over time using ANOVA for   
lobar constellations of Brodmann’s areas and then to further 
localize the differences by using follow-up t tests for   
between-group comparisons of individual Brodmann’s areas. 
Separate analyses of variance were thus performed for the 
cingulate gyrus, frontal, temporal, parietal, and occipital 
lobes. Then, in order to describe a prevailing overall pattern 
of between-group differences we contrasted frontal, tempo-
ral, and parietal lobes (each comprising 11 Brodmann’s   
areas) in a single analysis (see Tables 2, 3, 4 and 5 for group-
ings of individual Brodmann’s areas in regional contrasts).  
  Since there were significant differences in age among 
patients with different outcomes in our cohort, we employed 
ANCOVA with age at initial scan and length of the interval 
between the baseline and follow-up scans as covariates. 
There also were significant differences in illness duration 
among the two patient groups (as conservatively judged by 
years between the first exposure to neuroleptic treatment and 
initial MRI scan), which is known to be associated with 
lower gray matter volumes [54, 55]. We therefore ran   
ANCOVAs controlling for all 3 potential sources of system-
atic bias (illness duration, age at first scan and interscan   
interval). Since illness duration was not available for 5   
patients, we tabulate both analyses (with and without illness 
duration as covariate) and comment on the differential   
results in the text. All analyses were performed for both   
absolute and relative tissue volumes, with very similar   
results. Absolute gray and white matter volumes for each 
Brodmann’s area were divided by total brain gray and white 
matter volume respectively to convert them into relative 
volumetric data. Similarly, in order to correct for any poten-
tial variation over time, average fractional anisotropy values 
for each Brodmann’s area were divided by the average   
fractional anisotropy value of the whole-brain white matter, 
which yielded relative fractional anisotropy values used in 
the current analyses.  
  In order to put the longitudinal data in proper perspec-
tive, we analyzed baseline between-group differences in   
volumes and anisotropy first. For analyses of between-group 
differences in tissue volumes and anisotropy at baseline, we 
entered relative gray matter volume, white matter volume or 
fractional anisotropy values into a three-way ANCOVA (age 
as covariate) with independent diagnostic groups (schizo-
phrenia patients and healthy subjects or good-outcome and 
poor-outcome patients) and repeated measures for hemi-
sphere (left and right), specific Brodmann’s areas within 
each region (e.g. 23, 24, 25, 26, 29, 30, 31, 32 for the cingu-
late gyrus). For longitudinal analyses, we entered gray matter 
volume, white matter volume, or fractional anisotropy values 
into a 4-way ANCOVA with independent diagnostic groups 
(schizophrenia patients and healthy subjects or good-
outcome and poor-outcome patients) and repeated measures 
for time (baseline and follow-up scans), hemisphere (left and 
right), specific Brodmann’s areas within each analyzed   
region (e.g. 20, 21, 22, 27, 28, 34, 35, 36, 37, 38, 41, 42 for 
the temporal lobe analysis). For an overall contrast of the 
frontal, temporal, and parietal lobes, as well as a contrast of 
the medial and lateral temporal regions, a 5-way ANCOVA 
was used with independent diagnostic groups (schizophrenia 
patients and healthy subjects or good-outcome and poor-
outcome patients) and repeated measures for time (baseline 
and follow-up scans), hemisphere (left and right), region 
(frontal, temporal, and parietal; or medial temporal and   
lateral temporal), Brodmann’s areas within each region   
(e.g. 4, 6, 8, 9, 10, 11, 12, 44, 45, 46, 47 for the frontal lobe). 
Significant diagnostic group by time and higher-order (group 
by time by Brodmann’s area, group by time by hemisphere 
by Brodmann’s area) interactions were documented, each 
significant interaction was subjected to the Huynh-Feldt   
procedure for degree-of-freedom correction and graphs   
were examined for any discernable patterns of differential 
longitudinal changes, - all described in the results section. 
  Note that Brodmann’s areas 1, 2, 3, and 5 were combined 
into a single area (1-2-3-5) in our analyses because of   
the difficulties in their individual parcellation. Follow-up 
Student’s t tests were done for baseline minus follow-up 
volumetric and anisotropy values (difference scores) for   
individual Brodmann’s areas to localize the sources of   
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area. Finally, in order to explore the predictive value of illness 
severity at baseline for longitudinal volume/anisotropy 
change we examined the Pearson’s r product-moment corre-
lations between the baseline minus follow-up difference 
scores (gray and white matter volumes, white matter   
fractional anisotropy values) in 40 individual Brodmann’s 
areas and the PANSS subscale scores (positive, negative, 
general) at the time of the baseline scan. We hypothesized 
that among all patients with schizophrenia those with more 
severe psychopathology at presentation will display more 
pronounced tissue loss in the period to follow-up.  
RESULTS  
Schizophrenia Patients vs. Healthy Comparison Subjects 
Baseline Assessment of Regional White Matter Anisotropy 
  At baseline, white matter fractional anisotropy was lower 
in schizophrenia patients than in healthy subjects in the   
Table  2.  Significant ANCOVA Interactions for Between-Group Differences in Relative Gray Matter Volumes, Relative White   
Matter Volumes, and Fractional Anisotropy at Baseline Scan 
Brodmann’s Area Contrasts  Gray Matter Volumes  White Matter Volumes  Fractional Anisotropy 
Frontal lobe 
(4-6-8-9-10-11-12-24-25-32-44-45-46-47)      
   Schizophrenia vs. healthy subjects ME  F1, 62=10.28, p=0.0002     
  gBA F13, 806=2.65, p=0.001 (0.057) g BA F13, 806=3.09, p=0.0002 (0.038)   
     g hBA F13, 572=3.43, p=0.00004 (0.0008) 
   Good-outcome vs. poor-outcome    gh F1, 46=5.52, p=0.02 (0.02)  ghBA F13, 403=3.77, p=0.00001 (0.0003) 
Temporal lobe 
(20-21-22-27-28-34-35-36-37-38-41-42)      
   Schizophrenia vs. healthy subjects  ME F1, 62=11.55, p=0.001     
 g BA F11, 682=3.77, p=0.00003 (0.003)     
   Good-outcome vs. poor-outcome    ME F1, 46=8.10, p=0.007   
 g h F1, 46=4.43, p=0.04 (0.04)  gh F1, 46=8.53, p=0.005 (0.005)   
   gBA F11, 506=1.95, p=0.03 (0.10)  
 g hBA F11, 506=3.23, p=0.0003 (0.005)  ghBA F11, 506=4.13, p=0.000008 (0.002)   
Parietal lobe 
(1/2/3/5-7a-7b-23-26-29-30-31-39-40-43)      
   Schizophrenia vs. healthy subjects ME  F1, 62=4.9, p=0.03    ME F1, 44=4.52, p=0.04 
  gBA F10, 620=2.05, p=0.03 (0.11)   g BA F10, 440=2.31, p=0.01 (0.05) 
  ghBA F10, 620=2.06, p=0.025 (0.10)     
   Good-outcome vs. poor-outcome    ME F1, 46=3.95, p=0.053  
   g BA F10, 460=1.89, p=0.045 (0.13)  gBA F10, 310=2.59, p=0.005 (0.03) 
 g hBA F10, 460=3.51, p=0.0002 (0.014)  ghBA F10, 460=8.32, p=0000001 (0.000003)   
Occipital lobe 
(17-18-19)      
   Schizophrenia vs. healthy subjects      
   Good-outcome vs. poor-outcome g h F1, 46=6.29, p=0.016 (0.016)  gh F1, 46=5.76, p=0.02 (0.02) g h F1, 44=3.77, p=0.059 (0.059) 
Cingulate gyrus 
(23-24-25-26-29-30-31-32)      
   Schizophrenia vs. healthy subjects ME  F1, 62=11.11, p=0.0015    
    gh F1, 62=5.10, p=0.03 (0.03)  
 g BA F7, 434=6.32, p=0.0000001 (0.00003)  gBA F7, 434=2.33, p=0.02 (0.06)   
   Good-outcome vs. poor-outcome       
Abbreviations: ME – main effect of diagnosis, gh – diagnostic group by hemisphere interaction, gBA – diagnostic group by Brodmann’s area interaction, ghBA – diagnostic 
group by hemisphere by Brodmann’s area interaction.  
Uncorrected p values are followed by Huynh-Feldt corrected p in parentheses. Interactions at trend level of significance (p<0.10) are in italics. Note that parietal areas 1, 2, 3, and 5 
were combined in these analyses, hence 1/2/3/5. 36    The Open Neuroimaging Journal, 2009, Volume 3  Mitelman et al. 
frontal areas 9, 11, 12, 32 in the left hemisphere and 9, 25, 
44, 45, 46 in the right hemisphere, as well as in all parietal 
areas except 26, 40, and 43 (see Table 2 for significant   
ANCOVA interactions at baseline). Follow-up t tests for 
individual Brodmann’s areas confirmed lower anisotropy 
values in schizophrenia patients in left areas 7a, 21, 23, 39, 
46 and right areas 7a, 23, 27, 31, 44. 
Longitudinal Assessment of Regional White Matter   
Anisotropy  
  Healthy subjects started with higher fractional anisotropy 
values but displayed a greater decline over time than patients 
with schizophrenia in the posterior frontal areas 4, 6, 8   
(especially in the right hemisphere), 10 and 11 in both hemi-
spheres, left area 32 and right areas 44, 45, and 47, as well as 
in the whole temporal lobe (significant grouptime interac-
tion for the temporal lobe; see Table 3 for significant   
ANCOVA interactions). Follow-up t-tests for baseline minus 
follow-up anisotropy differences in individual Brodmann’s 
areas confirmed this pattern for right orbitofrontal area 11. 
The only Brodmann’s areas where patients with schizophre-
nia exhibited a greater decline in anisotropy than healthy 
subjects in the frontal lobe ANCOVA were left anterior cin-
gulate area 24 and orbitofrontal area 12 in both hemispheres. 
Entering 11 Brodmann’s areas from each of the frontal,   
temporal, and parietal lobes in a 5-way ANCOVA yielded a 
highly significant grouptime interaction (p=0.0064),   
confirming an overall pattern of steeper decline in fractional 
Table 3.  Significant ANCOVA Interactions for Between-Group Differences in Longitudinal Changes of White Matter Fractional 
Anisotropy  
Brodmann’s Area Contrasts  Fractional Anisotropy
a  Fractional Anisotropy  
Controlled for Illness Duration
b 
Frontal lobe 
(4-6-8-9-10-11-12-24-25-32-44-45-46-47)    
Schizophrenia vs. healthy subjects g thBA F13, 559=2.92, p=0.0004 (0.002)   
Good-outcome vs. poor-outcome g tBA F13, 390=2.16, p=0.01 (0.03)  gtBA F13, 338=2.17, p=0.01 (0.029) 
Temporal lobe 
(20-21-22-27-28-34-35-36-37-38-41-42) gt F1, 43=4.68, p=0.036 (0.036)   
Schizophrenia vs. healthy subjects    
Good-outcome vs. poor-outcome    
Parietal lobe 
(1/2/3/5-7a-7b-23-26-29-30-31-39-40-43)    
Schizophrenia vs. healthy subjects    
Good-outcome vs. poor-outcome g tBA F10, 300=2.49, p=0.007 (0.034)  gtBA F10, 260=2.19, p=0.02 (0.057) 
 g thBA F10, 300=2.58, p=0.005 (0.019)  gthBA F10, 260=2.58, p=0.01 (0.036) 
Occipital lobe 
(17-18-19)    
Schizophrenia vs. healthy subjects g t F1, 30=4.85, p=0.036 (0.036)   
Good-outcome vs. poor-outcome g tBA F2, 60=9.21, p=0.0003 (0.0003)  gtBA F2, 52=7.49, p=0.001 (0.001) 
Cingulate gyrus 
(23-24-25-26-29-30-31-32)    
Schizophrenia vs. healthy subjects    
Good-outcome vs. poor-outcome  gthBA F7, 210=2.11, p=0.044 (0.06)  
Frontal (4-6-8-9-10-11-12-44-45-46-47) vs. 
temporal (20-21-22-27-28-34-35-36-38-41-42) vs. 
parietal (1/2/3/5-7a-7b-23-26-29-30-31-39-40-43) 
Schizophrenia vs. healthy subjects  gtrBA F20, 600=1.74, p=0.02 (0.09)   
 g thrBA  F20, 600=2.13, p=0.003 (0.02)   
Good-outcome vs. poor-outcome g t F1, 30=6.65, p=0.015 (0.015)  gthrBA F20, 520=1.90, p=0.01 (0.04) 
Abbreviations: gt – diagnostic group by scan time interaction, gtBA – diagnostic group by time by Brodmann’s area interaction, gthBA – diagnostic group by time by hemi-
sphere by Brodmann’s area interaction, gtrBA – diagnostic group by time by region by Brodmann’s area interaction, gthrBA – diagnostic group by time by hemisphere by 
region by Brodmann’s area interaction. 
Uncorrected p values are followed by Huynh-Feldt corrected p in parentheses. Interactions at trend level of significance (p<0.10) are in italics. Note that parietal areas 1, 2, 3, and 5 
were combined in these analyses, hence 1/2/3/5. 
a ANCOVA with subjects’ age and interscan interval as covariates 
b ANCOVA with subjects’ age, interscan interval and illness duration as covariates. Longitudinal Assessment of Gray and White Matter in Chronic  The Open Neuroimaging Journal, 2009, Volume 3    37 
anisotropy values in healthy subjects as compared to patients 
with schizophrenia. Separate analyses of the cingulate   
arch, parietal, and occipital lobes produced no significant 
interactions. 
Baseline Assessment of Regional White Matter Volumes 
  Schizophrenia patients showed a pattern of larger relative 
white matter volumes than healthy subjects in the posterior 
frontal areas 4, 6, and to a lesser degree 8 (Table 2). White 
matter volumes were smaller in patients with schizophrenia 
than in healthy subjects in the anterior cingulate area 24   
(especially in the right hemisphere) and to a lesser degree in 
the orbitofrontal area 11. Follow-up t tests for individual 
Brodmann’s areas confirmed larger white matter volumes   
in patients with schizophrenia in a contiguous region under-
lying left posterior frontal/postcentral areas 4, 6, 7a and 
smaller volumes in the anterior cingulate and orbital frontal 
areas (Fig. 1). 
Longitudinal Assessment of Regional White Matter   
Volumes 
  There were trend-level interactions for absolute volumes 
in the cingulate gyrus and parietal lobe, and no significant 
ANCOVA interactions in any of the relative volume analy-
ses (Table 4). Student’s t-tests for baseline minus follow-up 
volume differences in individual Brodmann’s areas yielded 
more widespread differences for the absolute than relative 
tissue volumes and indicated that healthy subjects expanded 
white matter volumes significantly more than patients with 
schizophrenia in isolated Brodmann’s areas of each lobe in 
both hemispheres (Fig. 1). 
Baseline Assessment of Regional Gray Matter Volumes  
  At baseline, schizophrenia patients had smaller relative 
gray matter volumes than healthy subjects in the whole fron-
tal, temporal, and parietal lobes (significant main effects of 
diagnosis, Table 2). As evidenced by higher-order interac-
tions, this pattern was observed in every Brodmann’s area in 
the frontal lobe, all areas in the temporal lobe with the exclu-
sion of areas 34 and 35 (especially marked in areas 21, 22, 
and 20), all areas in the parietal lobe (especially marked in 
areas 1-2-3-5, 31, 39, 40, and 43), and all cingulate areas 
with the exclusion of areas 25 and 26. Follow-up t tests for 
individual Brodmann’s areas strongly confirmed this pattern 
as illustrated in Fig. (2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Differences in baseline relative white matter volumes and their longitudinal changes between patients with schizophrenia 
and healthy subjects and between schizophrenia patients with good and poor outcomes
a. 
a Significant between-group differences   
as assessed with Student’s t test for each Brodmann’s area (two-tailed p-values are color-coded in the bar). Baseline volumes: Blue colors 
denote areas with smaller relative white matter volumes in patients with schizophrenia than in healthy subjects and in poor-outcome patients 
in comparison to patients with good outcome at two-tailed p<0.05 (indigo) and p<0.1 (trend, light-blue). Brown color indicates areas  
with larger white matter volumes in patients with schizophrenia than in healthy subjects. Longitudinal changes (relative volumes at baseline 
scan minus relative volumes at follow-up scan): Green colors indicate areas with greater volume increase in healthy subjects than in schizo-
phrenia patients at two-tailed p<0.05 (dark-green) and p<0.1 (trend, light-green). Red colors indicate areas with greater volume increase in 
poor-outcome patients than in patients with good outcome at p<0.05 (burgundy hue) and p<0.1 (trend, scarlet hue). 38    The Open Neuroimaging Journal, 2009, Volume 3  Mitelman et al. 
Table  4.  Significant ANCOVA Interactions for Between-Group Differences in Longitudinal Changes of Absolute and Relative 
White Matter Volumes 
Brodmann’s Area Contrasts  Absolute Volumes
a   Absolute Volumes Controlled 
for Illness Duration
b 
 Relative Volumes
a   Relative Volumes Controlled 
for Illness Duration
b 
Frontal lobe  
(4-6-8-9-10-11-12-24-25-32-44-45-46-47) 
Schizophrenia vs. healthy subjects         
Good-outcome vs. poor-outcome    gt F1, 38=5.24, p=0.028 (0.028)  gt F1, 45=4.07, p=0.0497 (0.0497)  gt F1, 38=4.81, p=0.035 (0.035) 
  gtBA F13, 585=2.46, p=0.003 
(0.07) 
gtBA F13, 494=4.08, 
p=0.000002 (0.01)  
gtBA F13, 585=2.73, p=0.0009 
(0.053) 
gtBA F13, 494=3.74, 
p=0.00001(0.016) 
Temporal lobe 
(20-21-22-27-28-34-35-36-37-38-41-42) 
Schizophrenia vs. healthy subjects  gtBA F11, 671=2.02, p=0.02 
(0.12) 
   
    gthBA F11, 671=1.89, 
p=0.037 (0.13) 
  
Good-outcome vs. poor-outcome  gt F1, 45=8.02, p=0.007 (0.007)  gt F1, 38=7.90, p=0.008 (0.008)  gt F1, 45=7.53, p=0.009 (0.009)  gt F1, 38=7.23, p=0.01 (0.01) 
  gtBA F11, 495=2.86, p=0.001 
(0.04) 
gtBA F11, 418=2.70, p=0.002 
(0.053) 
gtBA F11, 495=3.01, p=0.0007 
(0.04) 
gtBA F11, 418=2.91, p=0.001 
(0.049) 
Parietal lobe 
(1/2/3/5-7a-7b-23-26-29-30-31-39-40-43) 
Schizophrenia vs. healthy subjects  gthBA F10, 610=2.09, 
p=0.02 (0.09) 
    
Good-outcome vs. poor-outcome  gt F1, 45=4.11, p=0.048 (0.048)  gt F1, 38=4.63, p=0.038 (0.038)     
  gtBA F10, 450=2.15, p=0.02 
(0.10) 
gth F1, 38=4.07, p=0.051 
(0.051) 
  
  gthBA F10, 450=2.82, 
p=0.002 (0.02) 
gthBA F10, 380=2.68, 
p=0.0036 (0.025) 
    
Occipital lobe 
(17-18-19) 
Schizophrenia vs. healthy subjects         
Good-outcome vs. poor-outcome  gt F1, 45=4.16, p=0.047 (0.047)  gt F1, 38=4.40, p=0.04 (0.04)  gt F1, 45=4.9, p=0.032 (0.032)   gt F1, 38=4.70, p=0.037 (0.037) 
Cingulate gyrus 
(23-24-25-26-29-30-31-32) 
Schizophrenia vs. healthy subjects  gt F1, 61=3.79, p=0.056 (0.056)     
Good-outcome vs. poor-outcome         
Frontal (4-6-8-9-10-11-12-44-45-46-47) vs. 
temporal (20-21-22-27-28-34-35-36-38-41-42) vs.  
parietal (1/2/3/5-7a-7b-23-26-29-30-31-39-40-43)  
Schizophrenia vs. healthy subjects  
Good-outcome vs. poor-outcome  gt F1, 45=6.53, p=0.014 (0.014)  gt F1, 38=6.95, p=0.01 (0.01)  gt F1, 45=6.42, p=0.015 (0.015)  gt F1, 38=6.59, p=0.014 (0.014) 
  gtrBA F20, 760=21.73, 
p=0.024 (0.10) 
 gtrBA F20, 900=2.08, 
p=0.004 (0.04) 
gtrBA F20, 760=2.86, 
p=0.0003 (0.005) 
 
Abbreviations: gt – diagnostic group by scan time interaction, gtBA – diagnostic group by time by Brodmann’s area interaction, gthBA – diagnostic group by time by hemi-
sphere by Brodmann’s area interaction, gtrBA – diagnostic group by time by region by Brodmann’s area interaction, gthrBA – diagnostic group by time by hemisphere by 
region by Brodmann’s area interaction. 
Uncorrected p values are followed by Huynh-Feldt corrected p in parentheses. Interactions at trend level of significance (p<0.10) are in italics. Note that parietal areas 1, 2, 3, and 5 
were combined in these analyses, hence 1/2/3/5. 
aANCOVA with subjects’ age and interscan interval as covariates (full sample) 
bANCOVA with subjects’ age, interscan interval and illness duration as covariates (subsample of schizophrenia patients) 
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Fig. (2). Differences in baseline relative gray matter volumes and their longitudinal changes between patients with schizophrenia and 
healthy subjects and between schizophrenia patients with good and poor outcomes
a. 
a Significant between-group differences as assessed 
with Student’s t test for each Brodmann’s area (two-tailed p-values are color-coded in the bar). Baseline volumes: Blue colors denote areas 
with smaller relative gray matter volumes in patients with schizophrenia than in healthy subjects and in poor-outcome patients in comparison 
to patients with good outcome. Longitudinal changes (relative volumes at baseline scan minus relative volumes at follow-up scan): Green 
colors indicate areas with greater volume decline in healthy subjects than in schizophrenia patients at two-tailed p<0.05 (dark-green) and 
p<0.1 (trend, light-green). Red colors indicate areas with greater volume decline in schizophrenia patients than healthy subjects or in poor-
outcome patients than in patients with good outcome at p<0.05 (burgundy hue) and p<0.1 (trend, scarlet hue).  
Longitudinal Assessment of Regional Gray Matter   
Volumes  
  Absolute and relative volume analyses produced very 
similar results (Table 5). ANCOVAs for the medial and lat-
eral temporal regions indicated that healthy subjects entered 
the study with larger gray matter volumes and had a greater 
decline over time than patients with schizophrenia in both 
medial and lateral areas 22, 28 in the left hemisphere and 21, 
22, 28, 36 in the right hemisphere; only in area 42 (primary 
auditory cortex) and especially in the right hemisphere did 
patients with schizophrenia show a steeper volume decline 
than healthy comparison subjects. In the frontal lobe, there 
was a trend towards a similar pattern of greater volume   
decline in healthy subjects in most of the areas (and especially 
8, 9, and 10), except the posterior frontal areas 4 and 6, 
where patients with schizophrenia evidenced a greater   
decline in volumes than healthy subjects.  
  When 11 Brodmann’s areas from each of the frontal, 
temporal, and parietal lobes were entered into a 5-way   
ANCOVA, there was a trend towards a pattern of a steeper 
gray matter volume decline over the period to follow-up   
in healthy subjects than patients with schizophrenia in the 
frontal areas 9 and 10, to a lesser degree 32 and 44 and in  
the temporal areas 20, 21, 22, 28, 36, and 38. Only in the 
temporal areas 37 and 42, as well as frontal areas 4 and 6 did 
patients with schizophrenia display a trend towards greater 
longitudinal decline in gray matter volume than healthy 
comparison subjects. There were no significant interactions 
in the analyses of the cingulate arch, parietal or occipital 
lobes. Follow-up t-tests for baseline minus follow-up volume 
differences in individual Brodmann’s areas confirmed   
this pattern for selected frontotemporal areas as illustrated in 
Fig. (2).  
  There were no significant differences between healthy 
subjects and patients with schizophrenia in the longitudinal 
change in whole brain, total gray matter or total white matter 
volumes. 
Patients with Good Outcomes vs. Patients with Poor 
Outcomes 
Baseline Assessment of Regional White Matter Anisotropy  
  At baseline, patients with poor outcome showed a pattern 
of lower fractional anisotropy than patients with good   
outcome in the left frontal areas 10, 44, 45, 46 and in every 40    The Open Neuroimaging Journal, 2009, Volume 3  Mitelman et al. 
Table  5.  Significant ANCOVA Interactions for Between-Group Differences in Longitudinal Changes of Absolute and Relative 
Gray Matter Volumes 
Brodmann’s Area Contrasts  Absolute Volumes
a  Absolute Volumes Controlled 
for Illness Duration
b 
 Relative Volumes
a  Relative Volumes Controlled 
for Illness Duration
b 
Frontal lobe 
(4-6-8-9-10-11-12-24-25-32-44-45-46-47) 
Schizophrenia vs. healthy subjects  gtBA F13, 793=2.26, p=0.006 
(0.09) 
  gtBA F13, 793=2.17, 
p=0.009 (0.10) 
 
Good-outcome vs. poor-outcome    gt F1, 38=4.56, p=0.04 (0.04)     
    gtBA F13, 494=3.40, p=0.00005 
(0.03) 
  gtBA F13, 494=2.82, p=0.0007 
(0.052) 
Temporal lobe  
(20-21-22-27-28-34-35-36-37-38-41-42) 
Schizophrenia vs. healthy subjects     gtBA F11, 671=2.18, 
p=0.014 (0.088) 
 
Good-outcome vs. poor-outcome 
Lateral (20-21-22-41-42) vs. medial  
(27-28-34-35-36) temporal regions 
Schizophrenia vs. healthy subjects   gtrBA F4, 244=2.95, p=0.02 
(0.06) 
  gtrBA F4, 244=3.85, 
p=0.005 (0.02) 
 
  gthrBA F4, 244=2.97, p=0.02 
(0.04) 
    
Good-outcome vs. poor-outcome 
Parietal lobe 
(1/2/3/5-7a-7b-23-26-29-30-31-39-40-43) 
Schizophrenia vs. healthy subjects  
Good-outcome vs. poor-outcome  gt F1, 38=4.44, p=0.04 (0.04)        
  gtBA F10, 450=2.28, p=0.01 
(0.09) 
gtBA F10, 380=2.67, p=0.004 
(0.054) 
gtBA F10, 450=2.35, 
p=0.01 (0.08) 
gtBA F10, 380=2.26, p=0.01 
(0.09) 
  gthBA F10, 450=2.60, 
p=0.0045 (0.057)  
gthBA F10, 380=2.60, 
p=0.000004 (0.004) 
gthBA F10, 450=2.87, 
p=0.0017 (0.036) 
gthBA F10, 380=4.51, 
p=0.000005 (0.003) 
Occipital lobe 
(17-18-19) 
Schizophrenia vs. healthy subjects 
Good-outcome vs. poor-outcome   gthBA F2, 76=4.12, p=0.02 
(0.036) 
  
Cingulate gyrus  
(23-24-25-26-29-30-31-32) 
Schizophrenia vs. healthy subjects 
Good-outcome vs. poor-outcome    gt F1, 38=6.59, p=0.014 0.014)   gt F1, 38=4.12, p=0.0496 
(0.0496) 
     gtBA F7, 266=3.14, p=0.003 
(0.028) 
  gtBA F7, 266=2.34, p=0.025 
(0.075) 
Frontal (4-6-8-9-10-11-12-44-45-46-47) vs. 
temporal (20-21-22-27-28-34-35-36-38-41-42) vs.  
parietal (1/2/3/5-7a-7b-23-26-29-30-31-39-40-43)  
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Table 5 cont…. 
Brodmann’s Area Contrasts  Absolute Volumes
a  Absolute Volumes Controlled 
for Illness Duration
b 
 Relative Volumes
a  Relative Volumes Controlled 
for Illness Duration
b 
Schizophrenia vs. healthy subjects  gtrBA F20, 1220=1.85, p=0.01 
(0.08) 
  gtrBA F20, 1220=1.92, 
p=0.009 (0.06) 
 
    gthrBA F20, 1220=2.42, 
p=0.0006 (0.054) 
gthrBA F20, 1220=2.42, 
p=0.0005 (0.052) 
 
Good-outcome vs. poor-outcome g t F1, 45=4.06, p<0.05 (<0.05)  gt F1, 38=4.52, p=0.04 (0.04)    gtrBA F2, 76=4.31, p=0.017 
(0.017) 
  gtrBA F20, 760=1.90, p=0.01 
(0.096) 
  
Abbreviations: gt – diagnostic group by scan time interaction, gtBA – diagnostic group by time by Brodmann’s area interaction, gthBA – diagnostic group by time by hemi-
sphere by Brodmann’s area interaction, gtrBA – diagnostic group by time by region by Brodmann’s area interaction, gthrBA – diagnostic group by time by hemisphere by 
region by Brodmann’s area interaction 
Uncorrected p values are followed by Huynh-Feldt corrected p in parentheses. Interactions at trend level of significance (p<0.10) are in italics. Note that parietal areas 1, 2, 3, and 5 
were combined in these analyses, hence 1/2/3/5. 
aANCOVA with subjects’ age and interscan interval as covariates (full sample of participants) 
bANCOVA with subjects’ age, interscan interval and illness duration as covariates (subsample of schizophrenia patients).  
parietal area except 1-2-3-5, 7a, and 7b, where anisotropy 
was higher in the poor-outcome group (Table 2). Follow-up 
t-tests for individual Brodmann’s areas did not produce   
significant results. 
Longitudinal Assessment of Regional White Matter   
Anisotropy  
  Patients with schizophrenia with good outcome started 
with higher anisotropy values but displayed a steeper decline 
over time than patients with poor outcome in Brodmann’s 
areas 9, 23, 24 (especially in the left hemisphere), 25, 44, 45, 
47 in both hemispheres, right area 31 and left area 43 (see 
interactions for the frontal, parietal, and cingulate analyses in 
Table 3 and diagram in Fig. (3). Entering 11 Brodmann’s 
areas from each of the frontal, temporal, and parietal lobes 
into a 4-way ANCOVA yielded a significant diagnostic 
grouptime interaction, suggesting an overall pattern of 
greater decline in fractional anisotropy over time in patients 
with good outcome everywhere with the exception of the 
occipital lobes. Controlling for illness duration slightly 
weakened the results but did not principally change them. 
  Poor-outcome patients showed a greater increase in   
fractional anisotropy values over time than patients with 
good outcome in areas 17, 18, 26, 30 in both hemispheres, 7a 
and 29 in the left hemisphere, as well as overall in the   
occipital lobe (significant diagnostic grouptime and higher-
order interactions for the occipital lobe, see also significant 
interactions for the parietal lobe and cingulate arch). Poor-
outcome patients showed a greater decline in anisotropy than 
patients with good outcome in the frontal areas 4, 6, and 12 
in both hemispheres, as well as right parietal areas 1-2-3-5, 
7a, 7b, and 43 (see significant interactions for the frontal and 
parietal lobes in Table 3). Analyses of the temporal lobe and 
follow-up t tests for individual Brodmann’s areas yielded no 
significant results.  
Baseline Assessment of Regional White Matter Volumes  
  At baseline, patients with poor outcome had smaller   
relative white matter volumes than patients with good out-
come in the whole temporal and occipital lobes (significant 
main effects of diagnosis), more pronounced in the right 
hemisphere, and at a trend level in the whole parietal lobe 
(Table  2). Based on the higher-order interactions, this   
was evident in every temporal area except right area 42   
(especially marked in areas 20, 21, 22, 36, and left area 42) 
and in the parietal areas 39, 40, and left area 1-2-3-5.   
Follow-up t tests for individual Brodmann’s areas confirmed 
smaller white matter volumes in the poor-outcome group   
in a set of temporal, restrosplenial cingulate and isolated 
frontoparietal areas (Fig. 1). 
Longitudinal Assessment of Regional White Matter   
Volumes  
  Absolute and relative volume analyses yielded similar 
results (Table 4). As the overall pattern of longitudinal 
 
 
 
Fig. (3). Composite ANCOVA-based
a diagram of the differences in longitudinal changes in white matter anisotropy between schizo-
phrenia patients with good and poor outcomes. 
aSignificant diagnostic grouptimeBrodmann’s area interactions in all ANCOVAs are 
illustrated based on the decomposition of the mean effects for individual Brodmann’s areas. Lilac color indicates areas with greater anisot-
ropy decline in patients with good outcome than in patients with poor outcome. Khaki color indicates areas with greater anisotropy decline 
in patients with poor outcome than in patients with good outcome. Green color indicates areas with greater anisotropy increase in patients 
with poor outcome than in patients with good outcome. Areas with between-group ANCOVA differences in relative anisotropy of less than 
0.2 points were left blank. 42    The Open Neuroimaging Journal, 2009, Volume 3  Mitelman et al. 
changes in white matter volumes, poor-outcome schizophre-
nia patients started with smaller volumes but expanded over 
time significantly more than patients with good outcome. 
This was evident in the whole frontal lobe (significant   
diagnostic grouptime interaction) with localized differences 
in the frontal areas 4, 6, 8, 9, 10, and, to a lesser extent, 46 
(significant diagnostic grouptimeBrodmann’s area interac-
tion); in the whole temporal lobe (highly significant diagnos-
tic grouptime interaction), specifically in areas 20, 21, 22, 
28, 36, 37, and 38 (significant diagnostic grouptime 
Brodmann’s area interaction); and in the whole occipital lobe 
(significant diagnostic grouptime interaction). In addition, 
absolute but not relative volume analyses evidenced the 
same pattern in the parietal lobe as well (significant diagnos-
tic grouptime interaction), specifically in the right areas   
1-2-3-5, 39, and 40 (significant diagnostic grouptime 
hemisphereBrodmann’s area interaction). Entering 11 
Brodmann’s areas from each of the frontal, temporal,   
and parietal lobes into an ANCOVA yielded a significant 
diagnostic grouptime interaction, suggestive of an overall 
pattern of greater white matter volume expansion in the 
poor-outcome schizophrenia group. Controlling for illness 
duration strengthened these results for the frontal lobe and 
slightly weakened the results for the temporal lobe, leaving 
everything else principally unchanged. ANCOVA for the 
cingulate arch did not produce significant interactions. 
  Follow-up t-tests for baseline minus follow-up volume 
differences in individual Brodmann’s areas similarly   
indicated that patients with poor outcome expanded white 
matter volumes over time significantly more than those with 
good outcome in the temporal and orbitofrontal areas and at 
a trend level throughout the brain (Fig. 1). 
Baseline Assessment of Regional Gray Matter Volumes  
  At baseline, patients with poor outcome showed a pattern 
of smaller relative gray matter volumes than patients with 
good outcome in all temporal areas except areas 34, 35, and 
right area 42 (especially marked decreases in left areas 21, 
22, 36, and 37) and in almost all parietal areas (especially 
marked in areas 7b, 31, 39, 40, 43, and left 1-2-3-5). In the 
occipital lobe, the difference in gray matter volumes between 
good-outcome and poor-outcome patients was more pro-
nounced in the right than in the left hemisphere (Table 2). 
Follow-up t-tests for individual Brodmann’s areas confirmed 
smaller gray matter volumes in poor-outcome patients in the 
anterior cingulate and posterior cerebral cortex (temporal, 
parietal, and occipital), more widespread in the left hemi-
sphere (Fig. 2).  
Longitudinal Assessment of Regional Gray Matter   
Volumes  
  Schizophrenia patients with poor outcome showed a 
greater decline in gray matter volumes over time than those 
with good outcome in the parietal areas 40 and 43 in both 
hemispheres, combined area 1-2-3-5 in the left hemisphere 
and area 31 in the right hemisphere, even though the poor-
outcome group started with already smaller volumes at initial 
scan (Table 5). Controlling for duration of illness strength-
ened the results markedly and especially for the absolute 
tissue volumes, producing significant diagnostic grouptime 
and higher order interactions in the frontal, parietal, and   
occipital lobe analyses, the cingulate gyrus, and an overall 
contrast analysis of the frontal, temporal, and parietal lobes. 
These results indicated that patients with poor outcomes had 
a significantly greater gray matter volume declines through-
out the brain with the exception of the temporal lobe. 
Higher-order interactions implicated into this pattern practi-
cally every Brodmann’s area in the frontal and parietal lobes, 
cingulate areas 25, 31, and 32, and the right occipital area 18. 
Follow-up t-tests for baseline minus follow-up volume   
differences in individual Brodmann’s areas confirmed greater 
decline in volumes in the poor-outcome group in subgenual 
cingulate, left parietal and right orbitofrontal areas (Fig. 2). 
  Comparison of longitudinal changes in total brain vol-
umes in schizophrenia patients with good and poor outcomes 
using Student’s t test pointed to a trend towards a differential 
decline in whole brain volume that was steeper in the poor-
outcome group (p=0.087). Total gray and white matter   
volumes did not show differential patterns of longitudinal 
change between these two patient groups. 
Correlations between Longitudinal Changes and PANSS 
Scores at First Scan 
  As the overall pattern of correlations between baseline 
PANSS subscale scores and longitudinal changes in regional 
brain volumes and anisotropy, schizophrenia patients with 
higher baseline PANSS scores showed greater expansion   
in relative white matter volumes and greater decline in   
fractional anisotropy values as well as relative gray matter 
volumes over the follow-up period.  
  General psychopathology subscale scores inversely   
correlated with changes in temporal and occipital white   
matter volumes (left areas 17, 41, and right areas 17, 34), 
and directly correlated with changes in gray matter volumes 
in left parietal areas 1-2-3-5 and 40. Positive syndrome  
subscale scores inversely correlated with longitudinal 
changes in parietal and occipital white matter volumes   
(left areas 17, 39, and right area 19), and directly correlated 
with changes in gray matter volumes in left areas 25 (sub-
genual cingulate) and 40 (lower parietal). Negative   
syndrome subscale scores inversely correlated with changes 
in white matter volumes associated with the right temporal 
area 34 and directly with fractional anisotropy values in   
left orbitofrontal areas 11, 12, 47 and right areas 1-2-3-5, 7a, 
7b, 43 (parietal), 10, 12 (frontal), and 17 (occipital), as well 
as with changes in gray matter volumes in left upper parietal 
area 7b. 
DISCUSSION 
Schizophrenia Patients and Healthy Subjects 
  In comparison to healthy subjects and in alliance with a 
large body of neuroimaging literature, middle-aged patients 
with chronic schizophrenia entered this study with lower 
anisotropy over extensive frontal and parietal white matter 
regions and with larger posterior frontal white matter   
volumes. As could be expected from the prior research, they 
also displayed reduced gray matter volumes throughout the 
frontal, temporal, and parietal lobes. These findings are   
almost identical to our published data from the full original 
sample of 145 participants and thus add a strong argument 
against any potential bias in the selection of the current   
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finding of larger white matter volumes at the frontoparietal 
junction was also recently presented by Whitford et al. in 
first-episode schizophrenia patients [36]. 
  In the longitudinal four-year follow-up in this study, 
healthy subjects exhibited regional reductions in fractional 
anisotropy and gray matter volumes, as well as expansion of 
regional white matter volumes over the follow-up period, - a 
pattern that is in agreement with available neuroimaging 
literature on normal aging in this age group as reviewed 
elsewhere [9, 13, 23].  As compared to healthy subjects,   
patients with schizophrenia displayed a pattern of slower 
decline in gray matter volumes and white matter anisotropy, 
as well as slower regional white matter expansion. There-
fore, overall changes in gray matter volumes, white matter 
volumes and white matter anisotropy were in the direction of 
an effacement of between-group differences, seen at baseline 
assessment.  
  We hypothesize that pathological changes in both gray 
and white matter in patients with schizophrenia occur pre-
morbidly and early in the course of their illness, and that the 
rate of these changes slows down with age. The differences 
between healthy and schizophrenia subjects in both gray 
matter and white matter volume as well as white matter   
anisotropy, seen at earlier stages of illness, then begin to 
diminish as if schizophrenia patients were ahead of healthy 
subjects in the normative process of aging. This underscores 
the importance of illness duration and age in comparative 
analyses of disparate neuroimaging data, which may be   
one of the reasons for the notorious heterogeneity of the 
structural findings in the literature reported to date. 
White Matter Anisotropy 
  For white matter fractional anisotropy, overall pattern for 
the frontal, temporal, and parietal white matter as a whole 
was that of a greater decline over time in healthy subjects 
than in patients with schizophrenia. The same pattern was 
more locally observed in the whole temporal lobe, as well as 
in several frontal regions, where it was more extensive in the 
right hemisphere. However, in the left anterior cingulate 
(underlying area 24) and in the orbitofrontal white matter in 
both hemispheres patients with schizophrenia showed a 
greater decline in anisotropy than healthy subjects. This   
latter finding is consistent with a differential timeframe of 
illness progression in various regions of the brain, with the 
possibility of a still active pathological process in the ante-
rior cingulate and orbitofrontal white matter at this stage of 
the illness course. 
White Matter Volumes 
  For white matter volumes, we observed a greater expan-
sion over time in healthy subjects than in patients with 
schizophrenia in the isolated right cingulate and temporal 
regions. These results contrast with those recently reported 
by van Haren et al. [35], who found a significantly more 
pronounced whole-brain white matter volume expansion in 
patients with schizophrenia than in healthy subjects in a 5-
year follow-up study. Participants in their study were 
younger than ours (32.22±11.10 vs. 42.69±12.29 years old 
for patients and 35.28±12.25 vs. 41.63±12.23 years old for 
healthy subjects at baseline scan), therefore one may con-
clude that this pattern of more pronounced white matter   
expansion in schizophrenia patients slows down and at least 
regionally begins to revert itself in the next decade of life. 
Indeed, in their regression by age analysis van Haren et al. 
[35] found that rate of the white matter expansion in schizo-
phrenia patients reduced with age down to a complete halt by 
approximately age 51, whereas white matter expansion pro-
gressed linearly in healthy comparison subjects throughout 
the investigated age range. Moreover, differences in the rate 
of white matter expansion between patients with schizophre-
nia and healthy subjects were significant only up to the age 
of 32 years. Our present study extends the results of van 
Haren et al. [35] by showing that later in life the differences 
in the rates of changes in white matter volumes not only   
become statistically indistinguishable but even begin to   
revert themselves at least regionally due to more pronounced 
white matter expansion in healthy subjects than in patients 
with schizophrenia.  
  It should be emphasized that the similarity of results for 
absolute and relative tissue volumes in our study mitigates 
against the possibility of white matter changes being created 
by a corresponding change in gray matter in the opposite 
direction. It should also be noted that in follow-up data each 
participant is their own control hence an absolute volumetric 
change in cubic millimeters is directly interpretable. Finally, 
based on our results white matter anisotropy may indeed be 
more sensitive a measure of longitudinal white matter 
changes in schizophrenia than volumetric analyses, as has 
previously been proposed for normal aging [16-18]. 
Gray Matter Volumes 
  For gray matter volumes, there was a greater decline over 
time in healthy subjects than in patients with schizophrenia 
in the lateral and medial temporal cortex, as well as the pre-
frontal region surrounding the pole (areas 9, 10, 32, and 44). 
Only in the upper lateral temporal area 42 (primary auditory 
cortex) and in the motor-premotor cortex did patients with 
schizophrenia continue to lose gray matter volume at a 
greater rate. Gur et al. [56] previously reported a similarly 
less pronounced gray matter volume reduction in the tempo-
ral lobe over a 2.5-year follow-up in chronic schizophrenia 
patients than in healthy comparison subjects. These authors 
compared rates of gray matter volume changes in first-
episode and chronic schizophrenia patients with normal   
aging changes in healthy subjects. They found that while the 
younger, first-episode schizophrenia patients displayed a 
greater decline in the frontal and temporal volumes than 
healthy comparison subjects, chronic schizophrenia patients 
displayed a less pronounced gray matter volume reduction in 
the temporal lobe and no difference in the frontal lobe as 
compared to healthy comparison subjects. In a small sample 
of men with chronic schizophrenia and closer to ours in age 
(39.4±6.4 for patients and 40.7±8.5 for healthy subjects), 
Mathalon  et al. [5] likewise report a trend towards faster 
decline in left prefrontal gray matter volume in healthy   
subjects than in patients with schizophrenia and a trend   
towards a reversed pattern in right prefrontal gray matter.  
  Our current results thus appear to confirm the findings of 
Gur et al. [56] for the temporal lobe and detect analogous 
pattern in a smaller prefrontal region, similar to the findings 
of Mathalon et al. [5]. In contrast, van Haren et al. [35]   
report that the continued gray matter volume loss in their 
younger longitudinal cohort was more pronounced in   
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subjects. In their study, the loss of gray matter with age   
accelerated in healthy subjects (between years 29 and 50) 
and slowed down in schizophrenia patients (up to age 56), so 
that the intergroup differences in the rate of the decline in 
volume in the frontal, temporal, and occipital lobes were 
only significant up to age 46, and in the parietal lobe only up 
to age 40. Our present findings show that with further aging 
the rate of gray matter loss in patients with schizophrenia 
eventually becomes even slower than in healthy comparison 
subjects, at least in some temporal and prefrontal regions, so 
that the between-group volumetric differences eventually 
begin to narrow. 
Schizophrenia Patients with Good and Poor Outcomes 
  As compared to the good-outcome group, schizophrenia 
patients with poor outcome entered the study with lower 
white matter anisotropy in the frontal and parietal lobes, as 
well as reduced white matter and gray matter volumes in the 
posterior (temporal, parietal, and occipital) regions of the 
brain. This was consistent with our earlier finding of the pos-
teriorization in the gray and white matter volume deficits 
with poor outcome in schizophrenia [39, 41] and of the more 
widespread anisotropy reductions in these patients [40]. Over 
the 4-year follow-up period, patients with poor outcome dis-
played a pattern of slower decline in white matter anisotropy 
and faster expansion of white matter volumes in comparison 
to patients with good outcome. Therefore, similarly to the 
longitudinal changes in all schizophrenia patients and 
healthy subjects, changes in white matter volume and anisot-
ropy in the good-outcome and poor-outcome schizophrenia 
subgroups were in the direction of an effacement of   
between-group differences, seen at baseline assessment. In 
contrast to this pattern, patients with poor outcome displayed 
a greater decline in gray matter volumes throughout the brain 
than patients with good outcome, indicative of a continued 
progression of the illness-related pathology in the poor-
outcome group. These changes were not associated merely 
with longer illness duration since effects had increased   
significance levels when illness duration was included as a 
covariate.  
White Matter Anisotropy 
  For white matter fractional anisotropy, the overall pattern 
for the frontal, parietal and temporal lobes was that of a 
lesser decline in patients with poor outcome than in those 
with good outcome (especially notable in the prefrontal and 
anteroposterior cingulate regions). This implies that the   
anisotropy deficits, documented in these patients throughout 
most of the brain [40], are the result of an earlier patho-
physiological process that took place before or for a rela-
tively limited period after the symptomatic onset of the   
disease. Moreover, at least in the third decade after the initial 
diagnosis the anisotropy differences among patients with 
different outcomes tend to diminish. Yet, a more pronounced 
decline in anisotropy in patients with poor outcome was seen 
in a contiguous region of the precentral/postcentral white 
matter (khaki areas in Fig. 3), which thus suggests a region-
ally localized progression of white matter pathology in the 
poor-outcome group even in the chronic phase of the illness. 
Further, in the occipital lobe and retrosplenial cingulate 
(green areas in Fig. 3) fractional anisotropy increased with 
time in both patient groups but significantly more so in   
patients with poor outcome. This increase in anisotropy may 
be the aftermath of an undetected co-territorial decline in 
white matter volume (we have previously documented an 
inverse relationship among the regional white matter   
volumes and anisotropy in this same group of patients [40]). 
Previous cross-sectional studies reported a positive correla-
tion between age and fractional anisotropy in tractographi-
cally placed seed points within specific tracts in both healthy 
and schizophrenia subjects [57, 58]. Small Brodmann’s areas 
26, 29, and 30 in the retrosplenial white matter are likely to  
incorporate mostly the posterior portion of the cingulum, 
where anisotropy increases with age and this effect may be 
accentuated by loss of the surrounding extrafascicular white 
matter in the poor-outcome patient group. The cause   
notwithstanding, the disparate anisotropy changes in the   
occipital and posterior cingulate white matter point to a   
progressive pathological process in patients with poor   
outcome in these two regions too. 
White Matter Volumes 
  For white matter volumes, there was an overall pattern of 
a greater volume expansion in patients with poor outcome 
than in the good-outcome group, involving all lobes. In the 
frontal lobe, this pattern was further localizable to the   
precentral (areas 4, 6, 8) and polar (areas 9, 10) regions. In 
this vein, van Haren et al. [35] reported a direct association 
between the increase in the whole-brain white matter volume 
and a number of hospitalizations during the period to follow-
up in a chronic schizophrenia patient group. 
Gray Matter Volumes  
  For gray matter, we found a greater cortical volume loss 
over time in patients with poor outcome throughout the 
brain. In a 5-year longitudinal voxel-based and region-of-
interest morphometry study in a younger group of partici-
pants, van Haren et al. [31, 35] showed that excessive   
decreases in the medial frontal polar (areas 9 and 10) and left 
upper temporal (area 42) gray matter density, as well as   
volume, were associated with a higher number of hospitali-
zations, i.e. more severe course of the illness in the Kraepe-
linian sense (see the outcome classification criteria in the 
Methods section). Mathalon et al. [5], too, found an associa-
tion between a more severe negative syndrome (as reflected 
by higher BPRS scores), as well as longer periods of hospi-
talization, and a greater decline in the prefrontal and tempo-
ral gray matter volume over time in a group of chronic 
schizophrenia patients. Davis et al. [59] reported a greater 
ventricular expansion over a 5-year period in chronic Kra-
epelinian schizophrenia patients in comparison to those with 
better outcomes. Taken together with these earlier results, 
our present findings support the notion of an association of 
the poor longitudinal outcome with the continued excessive 
loss of gray matter in patients with chronic schizophrenia. 
  It may be concluded, that albeit white matter volumes 
and anisotropy deficits in patients with poor outcome overall 
grew less conspicuous over time, there was evidence of the 
widespread illness progression in gray matter, as well as   
locally in the upper parietal/posterior frontal, retrosplenial 
cingulate, and occipital white matter in this patient group. 
Given the role that has lately been accorded to the progres-
sive white matter pathology of the aging brain in concurrent 
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in the posterior cerebral regions in the middle-aged poor-
outcome schizophrenia patients may in part be responsible 
for the steep cognitive and functional deterioration docu-
mented in these patients some two decades later in life [61-
63]. Further, it may also reflect the unremitting and treat-
ment-resistant course, characteristic of the Kraepelinian 
schizophrenia subtype, as compromised anisotropy indices 
observed during acute psychotic episodes have been shown 
to improve with treatment response and remission [64]. In 
contrast, clinical response to antipsychotic treatment (as seen 
in patients with good outcome) may be associated with de-
celeration of cortical gray matter loss, not seen in the treat-
ment-resistant poor-outcome patients with schizophrenia. 
Illness Severity at Study Entrance and Progressive Brain 
Changes 
  Schizophrenia patients with more severe symptomatol-
ogy at baseline presentation tended to exhibit greater expan-
sion in regional white matter volumes, as well as greater 
decline in white matter anisotropy and gray matter volumes 
over the follow-up period. In particular, schizophrenia   
patients with more severe negative symptoms at baseline 
assessment showed greater decline in white matter anisotropy 
over time in the left orbitofrontal and right upper parietal 
regions. Schizophrenia patients with more severe general 
psychopathology at baseline assessment displayed greater 
expansion in the temporal and occipital white matter   
volumes and greater reduction in the parietal gray matter 
volumes. Somewhat similar to our results, Cahn et al. [65] in 
a longitudinal schizophrenia study found that greater   
increase in white matter volumes over the first year of   
follow-up was predictive of higher PANSS positive   
syndrome subscale scores at 5-year follow-up. In contrast,  
in a 3-year follow-up study of first-episode schizophrenia 
patients, those with more severe negative symptoms tended 
to exhibit a greater reduction in frontal white matter volume 
[23], which once again suggests that the predominant   
patterns of volume change may differ at various stages of 
illness. 
Limitations of the Study 
  The limitations in this study include the number of   
participants lost to follow-up and imprecision in Brodmann’s 
area identification. While we retained close to half of our 
sample, the demographics and initial severity of rescanned or 
attrited subjects were extremely similar; further, the baseline 
patient/control differences in morphometric measures were 
very similar to our earlier reports on the full baseline sample 
of 145 subjects [40, 41], suggesting that major biases were 
not involved. Our mapping of the cortical Brodmann’s areas 
was based on microscopic examination of a single brain and 
thus should be treated as approximation. This is especially 
pertinent to the underlying white matter, which lacks   
consensual anatomical landmarks outside fascicles and can 
be only schematically described in relation to the cortical 
architectonic map. Our use of multiway ANOVA which 
combines related areas minimizes regional identification 
error as a proportion of the effect sizes observed. Lastly, due 
to the longitudinal design of the study - begun 8 years ago - 
some of the methodology (especially pertinent to the diffu-
sion-tensor imaging) inevitably lagged behind the rapid 
technical advances in the field. Future longitudinal assess-
ments should directly compare larger samples of first-
outbreak and chronic schizophrenia patients, employing 
newer acquisition techniques with smaller between-slice 
intervals, making it possible to evaluate changes in individ-
ual white matter tracts. 
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